Skip to main
PEN
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 35%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc has demonstrated significant growth in its business operations, highlighted by a remarkable 41% increase in VTE procedure volumes during December, marking its highest monthly performance to date. Additionally, the company's non-GAAP operating margin improved by 200 basis points year-over-year, driven by enhanced gross margins and reduced R&D expenses, reflecting operational efficiency. The overall sales figures for Thrombectomy and E&A segments also show upward trends, with Thrombectomy sales reaching $222.7 million, a 16.9% growth, and E&A sales increasing by 5.1%, indicative of strong market demand and effective product mix management.

Bears say

The financial analyst highlights significant concerns regarding Penumbra Inc.'s outlook, primarily driven by anticipated revenue growth decreasing to below 12% due to weaker-than-expected contributions from new products and sluggish profitability improvements. Notably, adjustments to revenue estimates for 2025 and 2026 reflect a downward revision, projecting revenues at $1.349 billion and $1.531 billion, respectively, illustrating a cautious adjustment in response to market challenges. Additionally, risks such as competitive pressures, potential supply chain disruptions, and the impact of COVID-19 variants further compound the negative sentiment surrounding the company’s financial performance and future growth prospects.

Penumbra (PEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 35% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 20 analysts, Penumbra (PEN) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.